Interestingly, the repurposing drug indacaterol identified also gave rise to pronounced synergistic anticancer activity when used in combination with a model first-generation EGFR specifically in NSCLC cells harboring EGFR T790M TKI gefitinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.